Concepedia

Eugenio Fernández

EF

Statistics

Publications

9

Citations

1.9K

H-Index

9

Active since

1997

Affiliations

The University of Sydney(Current)

University of Chicago

Dana-Farber Cancer Institute

Huntsman Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Eugenio Fernández is an author at The University of Sydney specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

1997–2025

9

Publications

9

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

Antoni Ribas, Reinhard Dummer, Igor Puzanov et al. · Cell · 2017 · 1.5K citations · Full text

, , +12

Hybrid Classifiers for Financial Multicriteria Decision Making: The Case of Bankruptcy Prediction

Ignacio Olmeda, Eugenio Fernández · Computational Economics · 1997 · 150 citations

, , +16

Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, Reinhard Dummer, Antoni Ribas et al. · Journal of Clinical Oncology · 2016 · 110 citations

, , +17

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)

Georgina V. Long, Reinhard Dummer, Antoni Ribas et al. · Journal for ImmunoTherapy of Cancer · 2015 · 33 citations · Full text

, , +17

Melanoma and immunotherapy bridge 2015

Vashisht Gopal Yennu Nanda, Weiyi Peng, Patrick Hwu et al. · Journal of Translational Medicine · 2016 · 24 citations · Full text

, , +17

1–5 of 9